Lilly: New breast cancer data from Verzenio and oral SERD programs at ASCO

 

• New exploratory analysis of a pre-specified subgroup of patients with HR+, HER2- high risk early breast cancer who received neoadjuvant chemotherapy in the monarchE trial showed Verzenio plus endocrine therapy resulted in a 6.6% absolute difference in invasive disease-free survival versus endocrine therapy alone
• First results from investigational oral selective estrogen receptor degrader (SERD) LY3484356 demonstrate pharmacokinetics, safety, and efficacy consistent with preclinical design
• Two Phase 3 trials to be initiated in 2021: Verzenio eMonarcHER trial in HR+, HER2+ high risk early breast cancer and oral SERD EMBER-3 trial in ER+, HER2- advanced breast cancer

https://www.newswire.ca/news-releases/lilly-announces-new-clinical-data-from-verzenio-and-oral-serd-programs-at-the-american-society-of-clinical-oncology-annual-meeting-859069920.html